NCT03678883 2026-04-03
9-ING-41 in Patients With Advanced Cancers
Actuate Therapeutics Inc.
Phase 2 Active not recruiting
Actuate Therapeutics Inc.
Dragonfly Therapeutics
Shanghai Yizhong Pharmaceutical Co., Ltd.
Eli Lilly and Company
Prescient Therapeutics, Ltd.
EpiAxis Therapeutics